Axovant Sciences Ltd. (NYSE:AXON) Files An 8-K Other Events
Item 8.01 Other Events.
On December14, 2018, Axovant Sciences Ltd. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Jefferies LLC, as representative of the several underwriters named therein, relating to the issuance and sale of 30,000,000 of the Company’s common shares (the “Offering”) at a price to the public of $1.00 per common share. The Company also granted the underwriters a 30-day option to purchase up to 4,500,000 additional common shares. The gross proceeds to the Company from the Offering, excluding the exercise by the underwriters of their 30-day option to purchase additional common shares, are expected to be $30,000,000 before deducting underwriting discounts and commissions and offering expenses payable by the Company. The Offering is scheduled to close on December18, 2018, subject to customary closing conditions.
The Underwriting Agreement contains customary representations, warranties, covenants and agreements the Company, indemnification obligations of the Company and the underwriters, including for liabilities under the Securities Act of 1933, as amended, other obligations of the parties and termination provisions. The representations, warranties and covenants contained in the Underwriting Agreement were made only for purposes of such agreement and as of specific dates, were solely for the benefit of the parties to the Underwriting Agreement, and may be subject to limitations agreed upon by the contracting parties.
The Offering is being made by means of a written prospectus supplement and accompanying prospectus forming part of a shelf registration statement on FormS-3 (Registration Statement No.333-215387), previously filed with the Securities and Exchange Commission (the “SEC”) and declared effective by the SEC on January13, 2017.
The Underwriting Agreement is attached as Exhibit1.1 hereto, and the description of the terms of the Underwriting Agreement is qualified in its entirety by reference to such exhibit. A copy of the opinion of Conyers Dill& Pearman Limited relating to the legality of the issuance and sale of the common shares in the Offering is attached as Exhibit5.1 hereto.
The disclosures on this Current Report on Form8-K shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
Item 9.01 Financial Statements and Exhibits.
Axovant Sciences Ltd. Exhibit
EX-1.1 2 a18-41350_3ex1d1.htm EX-1.1 Exhibit 1.1 30,…
To view the full exhibit click
About Axovant Sciences Ltd. (NYSE:AXON)
Axovant Sciences Ltd., formerly Roivant Neurosciences Ltd., is a clinical-stage biopharmaceutical company focused on acquiring, developing and commercializing therapeutics for the treatment of dementia. The Company focuses on developing a pipeline of product candidates to address the cognitive, functional and behavioral aspects of dementia and related neurological disorders. The Company’s focus is to develop its lead product candidate, Intepirdine, which is a selective 5-hydroxytryptamine 6 (5-HT6) receptor antagonist for the treatment of Alzheimer’s disease and dementia with Lewy bodies (DLB). The Company also focuses on developing its second product candidate, Nelotanserin, which is a selective 5-HT2A receptor inverse agonist for the treatment of visual hallucinations in patients with DLB and rapid eye movement (REM) behavior disorder (RBD) in patients with DLB.